{"PubmedArticle": [{"MedlineCitation": {"OtherID": [], "SpaceFlightMission": [], "KeywordList": [["cancer-specific monoclonal antibody-based chimeric antigen receptor T\u00a0cells", "glioma", "oncolytic herpes virus", "podoplanin"]], "CitationSubset": [], "InvestigatorList": [], "OtherAbstract": [], "GeneralNote": [], "PMID": "35991754", "DateRevised": {"Year": "2022", "Month": "08", "Day": "23"}, "Article": {"Language": ["eng"], "ArticleDate": [{"Year": "2022", "Month": "07", "Day": "20"}], "ELocationID": ["10.1016/j.omto.2022.07.006"], "Journal": {"ISSN": "2372-7705", "JournalIssue": {"Volume": "26", "PubDate": {"Year": "2022", "Month": "Sep", "Day": "15"}}, "Title": "Molecular therapy oncolytics", "ISOAbbreviation": "Mol Ther Oncolytics"}, "ArticleTitle": "Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47\u0394 combination therapy against glioblastoma.", "Pagination": {"StartPage": "265", "EndPage": "274", "MedlinePgn": "265-274"}, "Abstract": {"AbstractText": ["Glioblastoma is a devastating malignant brain tumor with a\u00a0poor prognosis despite standard therapy. Podoplanin (PDPN), a type I transmembrane mucin-like glycoprotein that is overexpressed in various cancers, is a potential therapeutic target for the treatment of glioblastoma. We previously reported the efficacy of chimeric antigen receptor (CAR)-T cells using an anti-pan-PDPN monoclonal antibody (mAb; NZ-1)-based third-generation CAR in a xenograft mouse model. However, NZ-1 also reacted with PDPN-expressing normal cells, such as lymphatic endothelial cells, pulmonary alveolar type I cells, and podocytes. To overcome possible on-target-off-tumor effects, we produced a cancer-specific mAb (CasMab, LpMab-2)-based CAR. LpMab-2 (Lp2) reacted with PDPN-expressing cancer cells but not with normal cells. In this study, Lp2-CAR-transduced T\u00a0cells (Lp2-CAR-T) specifically targeted PDPN-expressing glioma cells while sparing the PDPN-expressing normal cells. Lp2-CAR-T also killed patient-derived glioma stem cells, demonstrating its clinical potential against glioblastoma. Systemic injection of Lp2-CAR-T cells inhibited the growth of a subcutaneous glioma xenograft model in immunodeficient mice. Combination therapy with Lp2-CAR-T and oncolytic virus G47\u0394, a third-generation recombinant herpes simplex virus (HSV)-1, further inhibited the tumor growth and improved survival. These findings indicate that the combination therapy of Lp2-CAR-T cells and G47\u0394 may be a promising approach to treat glioblastoma."], "CopyrightInformation": "\u00a9 2022 The Author(s)."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Neurosurgery, Nagoya University School of Medicine, Nagoya, Japan."}, {"Identifier": [], "Affiliation": "Department of Neurosurgery, Nagoya Central Hospital, Nagoya, Japan."}, {"Identifier": [], "Affiliation": "Division of Innovative Cancer Therapy, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan."}], "LastName": "Chalise", "ForeName": "Lushun", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The Institute of Innovation for Future Society, Nagoya University, Nagoya, Japan."}], "LastName": "Kato", "ForeName": "Akira", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Neurosurgery, Aichi Cancer Centre Hospital, Nagoya, Japan."}], "LastName": "Ohno", "ForeName": "Masasuke", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Neurosurgery, Nagoya University School of Medicine, Nagoya, Japan."}], "LastName": "Maeda", "ForeName": "Sachi", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA."}], "LastName": "Yamamichi", "ForeName": "Akane", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Neurosurgery, National Hospital Organization Nagoya Medical Center, Nagoya, Japan."}], "LastName": "Kuramitsu", "ForeName": "Shunichiro", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "East Nagoya Imaging Diagnosis Center, Nagoya, Japan."}], "LastName": "Shiina", "ForeName": "Satoshi", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biomolecular Engineering, Graduate School of Engineering, Nagoya University, Nagoya, Japan."}], "LastName": "Takahashi", "ForeName": "Hiromi", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The Institute of Innovation for Future Society, Nagoya University, Nagoya, Japan."}], "LastName": "Ozone", "ForeName": "Sachiko", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Neurosurgery, Nagoya University School of Medicine, Nagoya, Japan."}], "LastName": "Yamaguchi", "ForeName": "Junya", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Japan."}, {"Identifier": [], "Affiliation": "Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan."}], "LastName": "Kato", "ForeName": "Yukinari", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The Institute of Innovation for Future Society, Nagoya University, Nagoya, Japan."}], "LastName": "Rockenbach", "ForeName": "Yumi", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The Institute of Innovation for Future Society, Nagoya University, Nagoya, Japan."}, {"Identifier": [], "Affiliation": "Department of Neurosugery, Kawamura Medical Society Hospital, Gifu, Japan."}], "LastName": "Natsume", "ForeName": "Atsushi", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Innovative Cancer Therapy, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan."}], "LastName": "Todo", "ForeName": "Tomoki", "Initials": "T"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Mol Ther Oncolytics", "NlmUniqueID": "101666776", "ISSNLinking": "2372-7705"}, "CoiStatement": "The authors have no conflict of interest to declare."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl. J. Med. 2005;352:987\u2013996. doi: 10.1056/NEJMoa043330.", "ArticleIdList": ["10.1056/NEJMoa043330", "15758009"]}, {"Citation": "Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J., Janzer R.C., Ludwin S.K., Allgeier A., Fisher B., Belanger K., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459\u2013466. doi: 10.1016/S1470-2045(09)70025-7.", "ArticleIdList": ["10.1016/S1470-2045(09)70025-7", "19269895"]}, {"Citation": "Grupp S.A., Kalos M., Barrett D., Aplenc R., Porter D.L., Rheingold S.R., Teachey D.T., Chew A., Hauck B., Wright J.F., et al. Chimeric antigen receptor-modified T\u00a0cells for acute lymphoid leukemia. New Engl. J. Med. 2013;368:1509\u20131518. doi: 10.1056/NEJMoa1215134.", "ArticleIdList": ["10.1056/NEJMoa1215134", "PMC4058440", "23527958"]}, {"Citation": "Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H. Chimeric antigen receptor-modified T\u00a0cells in chronic lymphoid leukemia. New Engl. J. Med. 2011;365:725\u2013733. doi: 10.1056/NEJMoa1103849.", "ArticleIdList": ["10.1056/NEJMoa1103849", "PMC3387277", "21830940"]}, {"Citation": "Abramson J.S., McGree B., Noyes S., Plummer S., Wong C., Chen Y.-B., Palmer E., Albertson T., Ferry J.A., Arrillaga-Romany I.C. Anti-CD19 CAR T\u00a0cells in CNS diffuse large-B-cell lymphoma. New Engl. J. Med. 2017;377:783\u2013784. doi: 10.1056/NEJMc1704610.", "ArticleIdList": ["10.1056/NEJMc1704610", "28834486"]}, {"Citation": "Locke F.L., Neelapu S.S., Bartlett N.L., Siddiqi T., Chavez J.C., Hosing C.M., Ghobadi A., Budde L.E., Bot A., Rossi J.M., et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T\u00a0cell therapy in refractory aggressive lymphoma. Mol. Ther. : J. Am. Soc. Gene Ther. 2017;25:285\u2013295. doi: 10.1016/j.ymthe.2016.10.020.", "ArticleIdList": ["10.1016/j.ymthe.2016.10.020", "PMC5363293", "28129122"]}, {"Citation": "Kochenderfer J.N., Dudley M.E., Kassim S.H., Somerville R.P., Carpenter R.O., Stetler-Stevenson M., Yang J.C., Phan G.Q., Hughes M.S., Sherry R.M., et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T\u00a0cells expressing an anti-CD19 chimeric antigen receptor. J.\u00a0Clin. Oncol. 2015;33:540\u2013549. doi: 10.1200/jco.2014.56.2025.", "ArticleIdList": ["10.1200/jco.2014.56.2025", "PMC4322257", "25154820"]}, {"Citation": "Mount C.W., Majzner R.G., Sundaresh S., Arnold E.P., Kadapakkam M., Haile S., Labanieh L., Hulleman E., Woo P.J., Rietberg S.P., et al. Potent antitumor efficacy of anti-GD2 CAR T\u00a0cells in H3-K27M(+) diffuse midline gliomas. Nat. Med. 2018;24:572\u2013579. doi: 10.1038/s41591-018-0006-x.", "ArticleIdList": ["10.1038/s41591-018-0006-x", "PMC6214371", "29662203"]}, {"Citation": "Brown C.E., Alizadeh D., Starr R., Weng L., Wagner J.R., Naranjo A., Ostberg J.R., Blanchard M.S., Kilpatrick J., Simpson J., et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. New Engl. J. Med. 2016;375:2561\u20132569. doi: 10.1056/NEJMoa1610497.", "ArticleIdList": ["10.1056/NEJMoa1610497", "PMC5390684", "28029927"]}, {"Citation": "Morgan R.A., Yang J.C., Kitano M., Dudley M.E., Laurencot C.M., Rosenberg S.A. Case report of a serious adverse event following the administration of T\u00a0cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 2010;18:843\u2013851. doi: 10.1038/mt.2010.24.", "ArticleIdList": ["10.1038/mt.2010.24", "PMC2862534", "20179677"]}, {"Citation": "Ahmed N., Brawley V.S., Hegde M., Robertson C., Ghazi A., Gerken C., Liu E., Dakhova O., Ashoori A., Corder A., et al. Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T\u00a0cells for the immunotherapy of HER2-positive sarcoma. J.\u00a0Clin. Oncol. 2015;33:1688\u20131696. doi: 10.1200/jco.2014.58.0225.", "ArticleIdList": ["10.1200/jco.2014.58.0225", "PMC4429176", "25800760"]}, {"Citation": "Shiina S., Ohno M., Ohka F., Kuramitsu S., Yamamichi A., Kato A., Motomura K., Tanahashi K., Yamamoto T., Watanabe R., et al. CAR T\u00a0cells targeting podoplanin reduce orthotopic glioblastomas in mouse brains. Cancer Immunol. Res. 2016;4:259\u2013268. doi: 10.1158/2326-6066.cir-15-0060.", "ArticleIdList": ["10.1158/2326-6066.cir-15-0060", "26822025"]}, {"Citation": "Krishnan H., Rayes J., Miyashita T., Ishii G., Retzbach E.P., Sheehan S.A., Takemoto A., Chang Y.W., Yoneda K., Asai J., et al. Podoplanin: an emerging cancer biomarker and therapeutic target. Cancer Sci. 2018;109:1292\u20131299. doi: 10.1111/cas.13580.", "ArticleIdList": ["10.1111/cas.13580", "PMC5980289", "29575529"]}, {"Citation": "Mishima K., Kato Y., Kaneko M.K., Nishikawa R., Hirose T., Matsutani M. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol. 2006;111:483\u2013488. doi: 10.1007/s00401-006-0063-y.", "ArticleIdList": ["10.1007/s00401-006-0063-y", "16596424"]}, {"Citation": "Motomura K., Natsume A., Watanabe R., Ito I., Kato Y., Momota H., Nishikawa R., Mishima K., Nakasu Y., Abe T., et al. Immunohistochemical analysis-based proteomic subclassification of newly diagnosed glioblastomas. Cancer Sci. 2012;103:1871\u20131879. doi: 10.1111/j.1349-7006.2012.02377.x.", "ArticleIdList": ["10.1111/j.1349-7006.2012.02377.x", "PMC7659188", "22747609"]}, {"Citation": "Verhaak R.G., Hoadley K.A., Purdom E., Wang V., Qi Y., Wilkerson M.D., Miller C.R., Ding L., Golub T., Mesirov J.P., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98\u2013110. doi: 10.1016/j.ccr.2009.12.020.", "ArticleIdList": ["10.1016/j.ccr.2009.12.020", "PMC2818769", "20129251"]}, {"Citation": "Chandramohan V., Bao X., Kato Kaneko M., Kato Y., Keir S.T., Szafranski S.E., Kuan C.T., Pastan I.H., Bigner D.D. Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors. Int. J. Cancer. 2013;132:2339\u20132348. doi: 10.1002/ijc.27919.", "ArticleIdList": ["10.1002/ijc.27919", "PMC3809846", "23115013"]}, {"Citation": "Schacht V., Dadras S.S., Johnson L.A., Jackson D.G., Hong Y.K., Detmar M. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am. J. Pathol. 2005;166:913\u2013921. doi: 10.1016/s0002-9440(10)62311-5.", "ArticleIdList": ["10.1016/s0002-9440(10)62311-5", "PMC1602360", "15743802"]}, {"Citation": "Kahn H.J., Bailey D., Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod. Pathol. 2002;15:434\u2013440. doi: 10.1038/modpathol.3880543.", "ArticleIdList": ["10.1038/modpathol.3880543", "11950918"]}, {"Citation": "Roy S., Chu A., Trojanowski J.Q., Zhang P.J. D2-40, a novel monoclonal antibody against the M2A antigen as a marker to distinguish hemangioblastomas from renal cell carcinomas. Acta Neuropathol. 2005;109:497\u2013502. doi: 10.1007/s00401-005-0999-3.", "ArticleIdList": ["10.1007/s00401-005-0999-3", "15864611"]}, {"Citation": "Kato Y., Kaneko M.K. A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin. Sci. Rep. 2014;4:5924. doi: 10.1038/srep05924.", "ArticleIdList": ["10.1038/srep05924", "PMC4118152", "25080943"]}, {"Citation": "Fukuhara H., Ino Y., Todo T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci. 2016;107:1373\u20131379. doi: 10.1111/cas.13027.", "ArticleIdList": ["10.1111/cas.13027", "PMC5084676", "27486853"]}, {"Citation": "Desjardins A., Gromeier M., Herndon J.E., 2nd, Beaubier N., Bolognesi D.P., Friedman A.H., Friedman H.S., McSherry F., Muscat A.M., Nair S., et al. Recurrent glioblastoma treated with recombinant poliovirus. New Engl. J. Med. 2018;379:150\u2013161. doi: 10.1056/NEJMoa1716435.", "ArticleIdList": ["10.1056/NEJMoa1716435", "PMC6065102", "29943666"]}, {"Citation": "Kiyokawa J., Wakimoto H. Preclinical and clinical development of oncolytic adenovirus for the treatment of malignant glioma. Oncolytic Virotherapy. 2019;8:27\u201337. doi: 10.2147/ov.s196403.", "ArticleIdList": ["10.2147/ov.s196403", "PMC6817710", "31750274"]}, {"Citation": "Chiocca E.A., Rabkin S.D. Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol. Res. 2014;2:295\u2013300. doi: 10.1158/2326-6066.cir-14-0015.", "ArticleIdList": ["10.1158/2326-6066.cir-14-0015", "PMC4303349", "24764576"]}, {"Citation": "Kim M., Nitschke M., Sennino B., Murer P., Schriver B.J., Bell A., Subramanian A., McDonald C.E., Wang J., Cha H., et al. Amplification of oncolytic vaccinia virus widespread tumor cell killing by sunitinib through multiple mechanisms. Cancer Res. 2018;78:922\u2013937. doi: 10.1158/0008-5472.can-15-3308.", "ArticleIdList": ["10.1158/0008-5472.can-15-3308", "PMC6501576", "29259007"]}, {"Citation": "Mineta T., Rabkin S.D., Yazaki T., Hunter W.D., Martuza R.L. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. 1995;1:938\u2013943. doi: 10.1038/nm0995-938.", "ArticleIdList": ["10.1038/nm0995-938", "7585221"]}, {"Citation": "Todo T., Martuza R.L., Rabkin S.D., Johnson P.A. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc. Natl. Acad. Sci. USA. 2001;98:6396\u20136401. doi: 10.1073/pnas.101136398.", "ArticleIdList": ["10.1073/pnas.101136398", "PMC33479", "11353831"]}, {"Citation": "Ahmed N., Brawley V., Hegde M., Bielamowicz K., Kalra M., Landi D., Robertson C., Gray T.L., Diouf O., Wakefield A., et al. HER2-Specific chimeric antigen receptor-modified virus-specific T\u00a0cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncol. 2017;3:1094\u20131101. doi: 10.1001/jamaoncol.2017.0184.", "ArticleIdList": ["10.1001/jamaoncol.2017.0184", "PMC5747970", "28426845"]}, {"Citation": "Choi B.D., Curry W.T., Carter B.S., Maus M.V. Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons. Neurosurg. Focus. 2018;44:E13. doi: 10.3171/2018.2.focus17788.", "ArticleIdList": ["10.3171/2018.2.focus17788", "29852773"]}, {"Citation": "Akhavan D., Alizadeh D., Wang D., Weist M.R., Shepphird J.K., Brown C.E. CAR T\u00a0cells for brain tumors: lessons learned and road ahead. Immunological Rev. 2019;290:60\u201384. doi: 10.1111/imr.12773.", "ArticleIdList": ["10.1111/imr.12773", "PMC6771592", "31355493"]}, {"Citation": "Bagley S.J., Desai A.S., Linette G.P., June C.H., O'Rourke D.M. CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges. Neuro-Oncology. 2018;20:1429\u20131438. doi: 10.1093/neuonc/noy032.", "ArticleIdList": ["10.1093/neuonc/noy032", "PMC6176794", "29509936"]}, {"Citation": "Chuntova P., Downey K.M., Hegde B., Almeida N.D., Okada H. Genetically engineered T-cells for malignant glioma: overcoming the barriers to effective immunotherapy. Front. Immunol. 2018;9:3062. doi: 10.3389/fimmu.2018.03062.", "ArticleIdList": ["10.3389/fimmu.2018.03062", "PMC6357938", "30740109"]}, {"Citation": "Curran K.J., Pegram H.J., Brentjens R.J. Chimeric antigen receptors for T\u00a0cell immunotherapy: current understanding and future directions. J.\u00a0Gene Med. 2012;14:405\u2013415. doi: 10.1002/jgm.2604.", "ArticleIdList": ["10.1002/jgm.2604", "PMC4697438", "22262649"]}, {"Citation": "Lamers C.H., Sleijfer S., van Steenbergen S., van Elzakker P., van Krimpen B., Groot C., Vulto A., den Bakker M., Oosterwijk E., Debets R., Gratama J.W. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T\u00a0cells: clinical evaluation and management of on-target toxicity. Mol. Ther. 2013;21:904\u2013912. doi: 10.1038/mt.2013.17.", "ArticleIdList": ["10.1038/mt.2013.17", "PMC5189272", "23423337"]}, {"Citation": "Linette G.P., Stadtmauer E.A., Maus M.V., Rapoport A.P., Levine B.L., Emery L., Litzky L., Bagg A., Carreno B.M., Cimino P.J., et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T\u00a0cells in myeloma and melanoma. Blood. 2013;122:863\u2013871. doi: 10.1182/blood-2013-03-490565.", "ArticleIdList": ["10.1182/blood-2013-03-490565", "PMC3743463", "23770775"]}, {"Citation": "Rosewell Shaw A., Suzuki M. Oncolytic viruses partner with T-cell therapy for solid tumor treatment. Front. Immunol. 2018;9:2103. doi: 10.3389/fimmu.2018.02103.", "ArticleIdList": ["10.3389/fimmu.2018.02103", "PMC6160535", "30298067"]}, {"Citation": "Huang J., Zheng M., Zhang Z., Tang X., Chen Y., Peng A., Peng X., Tong A., Zhou L. Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma. Cancer Immunol. Immunother. 2021;70:2453\u20132465. doi: 10.1007/s00262-021-02856-0.", "ArticleIdList": ["10.1007/s00262-021-02856-0", "33543339"]}, {"Citation": "McGrath K., Dotti G. Combining oncolytic viruses with chimeric antigen receptor T\u00a0cell therapy. Hum. Gene Ther. 2021;32:150\u2013157. doi: 10.1089/hum.2020.278.", "ArticleIdList": ["10.1089/hum.2020.278", "PMC8336251", "33349123"]}, {"Citation": "Nishio N., Diaconu I., Liu H., Cerullo V., Caruana I., Hoyos V., Bouchier-Hayes L., Savoldo B., Dotti G. Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T\u00a0cells in solid tumors. Cancer Res. 2014;74:5195\u20135205. doi: 10.1158/0008-5472.can-14-0697.", "ArticleIdList": ["10.1158/0008-5472.can-14-0697", "PMC4167556", "25060519"]}, {"Citation": "Tanoue K., Rosewell Shaw A., Watanabe N., Porter C., Rana B., Gottschalk S., Brenner M., Suzuki M. Armed oncolytic adenovirus-expressing PD-L1\u00a0mini-body enhances antitumor effects of chimeric antigen receptor T\u00a0cells in solid tumors. Cancer Res. 2017;77:2040\u20132051. doi: 10.1158/0008-5472.can-16-1577.", "ArticleIdList": ["10.1158/0008-5472.can-16-1577", "PMC5392365", "28235763"]}, {"Citation": "O'Rourke D.M., Nasrallah M.P., Desai A., Melenhorst J.J., Mansfield K., Morrissette J.J.D., Martinez-Lage M., Brem S., Maloney E., Shen A., et al. A single dose of peripherally infused EGFRvIII-directed CAR T\u00a0cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Translational Med. 2017;9 doi: 10.1126/scitranslmed.aaa0984.", "ArticleIdList": ["10.1126/scitranslmed.aaa0984", "PMC5762203", "28724573"]}, {"Citation": "Ohno M., Ohkuri T., Kosaka A., Tanahashi K., June C.H., Natsume A., Okada H. Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts. J.\u00a0Immunother. Cancer. 2013;1:21. doi: 10.1186/2051-1426-1-21.", "ArticleIdList": ["10.1186/2051-1426-1-21", "PMC4019893", "24829757"]}, {"Citation": "Kato Y., Vaidyanathan G., Kaneko M.K., Mishima K., Srivastava N., Chandramohan V., Pegram C., Keir S.T., Kuan C.T., Bigner D.D., Zalutsky M.R. Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas. Nucl. Med. Biol. 2010;37:785\u2013794. doi: 10.1016/j.nucmedbio.2010.03.010.", "ArticleIdList": ["10.1016/j.nucmedbio.2010.03.010", "PMC2946889", "20870153"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "12", "Day": "23"}, {"Year": "2022", "Month": "7", "Day": "15"}, {"Year": "2022", "Month": "8", "Day": "22", "Hour": "4", "Minute": "16"}, {"Year": "2022", "Month": "8", "Day": "23", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "8", "Day": "23", "Hour": "6", "Minute": "1"}, {"Year": "2022", "Month": "7", "Day": "20"}], "PublicationStatus": "epublish", "ArticleIdList": ["35991754", "PMC9364057", "10.1016/j.omto.2022.07.006", "S2372-7705(22)00095-X"]}}], "PubmedBookArticle": []}